TMPRSS11D and metabolic dysfunction-associated steatotic liver disease: Consistent with the results of Hyo-Kyoung Choi's study, they found that rutin and its metabolites as novel histone acetyltransferase (HAT) inhibitors suppress the progression of nonalcoholic fatty liver disease.